FDA label 94707fd1-9572-46d1-88c9-15bc86bba701

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
1145af19-824f-4701-9620-ee1c76a892b5
SPL ID
94707fd1-9572-46d1-88c9-15bc86bba701
Version
5
Effective date
2013-01-03
Source export date
2026-11-13
Source partition
5
Source file
https://download.open.fda.gov/drug/label/drug-label-0005-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/e10f1fd48195fb7eda0be611a6e3c49a40fe34c69a9c2a8d9e3e3b897ac31621/drug-label-0005-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:08:32

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS Cardiovascular Disorders Acute and transient "flu-like" symptoms such as fever and chills induced by ACTIMMUNE at doses of 250 mcg/m 2 /day (greater than 10 times the weekly recommended dose) or higher may exacerbate pre-existing cardiac conditions. ACTIMMUNE should be used with caution in patients with pre-existing cardiac conditions, including ischemia, congestive heart failure or arrhythmia. Neurologic Disorders Decreased mental status, gait disturbance and dizziness have been observed, particularly in patients receiving ACTIMMUNE doses greater than 250 mcg/m 2 /day (greater than 10 times the weekly recommended dose). Most of these abnormalities were mild and reversible within a few days upon dose reduction or discontinuation of therapy. Caution should be exercised when administering ACTIMMUNE to patients with seizure disorders or compromised central nervous system function. Bone Marrow Toxicity Reversible neutropenia and thrombocytopenia that can be severe and may be dose related have been observed during ACTIMMUNE therapy. Caution should be exercised when administering ACTIMMUNE to patients with myelosuppression. Hepatic Toxicity Elevations of AST and/or ALT (up to 25-fold) have been observed during ACTIMMUNE therapy. The incidence appeared to be higher in patients less than 1 year of age compared to older children. The transaminase elevations were reversible with reduction in dosage or interruption of ACTIMMUNE treatment. Patients begun on ACTIMMUNE before age one year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified (see DOSAGE AND ADMINISTRATION : Dose Modification ).

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

ADVERSE REACTIONS The following data on adverse reactions are based on the subcutaneous administration of ACTIMMUNE at a dose of 50 mcg/m 2 , three times weekly, in patients with Chronic Granulomatous Disease (CGD) during an investigational trial in the United States and Europe. The most common adverse events observed in patients with CGD are shown in the following table: Percent of Patients Clinical Toxicity ACTIMMUNE CGD (n=63) Placebo CGD (n=65) Fever 52 28 Headache 33 9 Rash 17 6 Chills 14 0 Injection site erythema or tenderness 14 2 Fatigue 14 11 Diarrhea 14 12 Vomiting 13 5 Nausea 10 2 Myalgia 6 0 Arthralgia 2 0 Injection site pain 0 2 Miscellaneous adverse events which occurred infrequently in patients with CGD and may have been related to underlying disease included back pain (2 percent versus 0 percent), abdominal pain (8 percent versus 3 percent) and depression (3 percent versus 0 percent) for ACTIMMUNE and placebo treated patients, respectively. Similar safety data were observed in 34 patients with severe malignant osteopetrosis. ACTIMMUNE has also been evaluated in additional disease states in studies in which patients have generally received higher doses (>100 mcg/m 2 /three times weekly) administered by intramuscular or subcutaneous injection, or intravenous infusion. All of the previously described adverse reactions which occurred in patients with Chronic Granulomatous Disease have also been observed in patients receiving higher doses. Adverse reactions not observed in patients with Chronic Granulomatous Disease but reported in patients receiving ACTIMMUNE (Interferon gamma-1b) in other studies include: Cardiovascular —hypotension, syncope, tachyarrhythmia, heart block, heart failure, and myocardial infarction. Central Nervous System —confusion, disorientation, gait disturbance, Parkinsonian symptoms, seizure, hallucinations, and transient ischemic attacks. Gastrointestinal —dyspepsia, hepatic insufficiency, gastrointestinal bleeding, and pancreatitis, including pancreatitis with fatal outcome. General Disorders and Administration Site Conditions —malaise, injection site hemorrhage. Hematologic —deep venous thrombosis and pulmonary embolism. Immunological —increased autoantibodies, lupus-like syndrome. Metabolic —hyponatremia, hyperglycemia and hypertriglyceridemia. Musculoskeletal —clubbing, muscle spasms. Pulmonary —tachypnea, bronchospasm, and interstitial pneumonitis. Renal —reversible renal insufficiency. Other —chest discomfort, exacerbation of dermatomyositis. Abnormal Laboratory Test Values: Elevations of ALT and AST, neutropenia, thrombocytopenia, and proteinuria have been observed (see WARNINGS and PRECAUTIONS : Laboratory Tests ). No neutralizing antibodies to ACTIMMUNE have been detected in any Chronic Granulomatous Disease patients receiving ACTIMMUNE . Post-Marketing Experience Children with CGD less than 3 years of age: Data on the safety and activity of ACTIMMUNE in 37 patients under the age of 3 years was pooled from four uncontrolled post-marketing studies. The rate of serious infections per patient-year in this uncontrolled group was similar to the rate observed in the ACTIMMUNE treatment groups in controlled trials. Developmental parameters (height, weight and endocrine maturation) for this uncontrolled group conformed to national normative scales before and during ACTIMMUNE therapy. In 6 of the 10 patients receiving ACTIMMUNE therapy before age one year 2-fold to 25-fold elevations from baseline of AST and/or ALT were observed. These elevations occurred as early as 7 days after starting treatment. Treatment with ACTIMMUNE was interrupted in all 6 of these patients and was restarted at a reduced dosage in 4. Liver transaminase values returned to baseline in all patients and transaminase elevation recurred in one patient upon ACTIMMUNE rechallenge. An 11-fold alkaline phosphatase elevation and hypokalemia in one patient and neutropenia (ANC=525 cells/mm 3 ) in another patient resolved with interruption of ACTIMMUNE treatment and did not recur with rechallenge. In the post-marketing safety database clinically significant adverse events observed during ACTIMMUNE therapy in children under the age of three years (n=14) included: two cases of hepatomegaly, and one case each of Stevens-Johnson syndrome, granulomatous colitis, urticaria, and atopic dermatitis.

adverse reactions table

<table ID="t1" width="80%"> <thead> <tr> <td/> <td/> <th align="center" colspan="4">Percent of Patients</th> <td/> </tr> <tr> <th>Clinical Toxicity</th> <td/> <th align="center"> <content styleCode="italics">ACTIMMUNE</content> CGD (n=63)</th> <td/> <th align="center">Placebo CGD (n=65)</th> <td/> </tr> </thead> <tbody> <tr> <td>Fever</td> <td/> <td align="center">52</td> <td/> <td align="center">28</td> <td/> </tr> <tr> <td>Headache</td> <td/> <td align="center">33</td> <td/> <td align="center">9</td> <td/> </tr> <tr> <td>Rash</td> <td/> <td align="center">17</td> <td/> <td align="center">6</td> <td/> </tr> <tr> <td>Chills</td> <td/> <td align="center">14</td> <td/> <td align="center">0</td> <td/> </tr> <tr> <td>Injection site erythema or tenderness</td> <td/> <td align="center">14</td> <td/> <td align="center">2</td> <td/> </tr> <tr> <td>Fatigue</td> <td/> <td align="center">14</td> <td/> <td align="center">11</td> <td/> </tr> <tr> <td>Diarrhea</td> <td/> <td align="center">14</td> <td/> <td align="center">12</td> <td/> </tr> <tr> <td>Vomiting</td> <td/> <td align="center">13</td> <td/> <td align="center">5</td> <td/> </tr> <tr> <td>Nausea</td> <td/> <td align="center">10</td> <td/> <td align="center">2</td> <td/> </tr> <tr> <td>Myalgia</td> <td/> <td align="center">6</td> <td/> <td align="center">0</td> <td/> </tr> <tr> <td>Arthralgia</td> <td/> <td align="center">2</td> <td/> <td align="center">0</td> <td/> </tr> <tr> <td>Injection site pain</td> <td/> <td align="center">0</td> <td/> <td align="center">2</td> <td/> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.